Are There Molecular Signatures for Predicting Bladder Cancer Prognosis?

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2347-2348

  Lokeshwar, Vinata B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADVANCED CANCER; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CARCINOMA IN SITU; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DNA SEQUENCE; EDITORIAL; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT;

DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 33750498042     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.142     Document Type: Editorial

References (10)

1. Mhawech-Fauceglia P., Cheney R.T., and Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 106 (2006) 1205
2. Droller M.J. Bladder cancer. Curr Probl Surg 18 (1981) 205
3. Jones P.A., and Droller M.J. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. Semin Urol 11 (1993) 177
4. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y.C., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784
5. van Rhijn B.W., van der Kwast T.H., Vis A.N., Kirkels W.J., Boeve E.R., Jobsis A.C., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004) 1911
6. Bakkar A.A., Wallerand H., Radvanyi F., Lahaye J.B., Pissard S., Lecerf L., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63 (2003) 8108
7. Rieger-Christ K.M., Mourtzinos A., Lee P.J., Zagha R.M., Cain J., Silverman M., et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 98 (2003) 737
8. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005) 139
9. Hernandez S., Lopez-Knowles E., Lloreta J., Kogevinas M., Jaramillo R., Amoros A., et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11 (2005) 5444
10. van Rhijn B.W., Vis A.N., van der Kwast T.H., Kirkels W.J., Radvanyi F., Ooms E.C., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003) 1912